CHICAGO -- Transcatheter aortic valve replacement (TAVR) continued to hold its own against surgery for younger patients at low surgical risk, with the Evolut Low Risk trial now halfway to its goal of ...

Medtronic has reported late-breaking data from the randomised Evolut Low Risk Trial’s five-year outcomes of the Evolut transcatheter aortic valve replacement (TAVR) system in low-risk aortic stenosis ...

There’s room on the market for new TAVI valves as long as they can compete with the best in practice, a researcher says.

Medtronic, Abbott and Boston Scientific had updates on their devices used in heart valve disease treatment at the event.

For over a decade, the McGill University Health Centre (MUHC) has been at the forefront of aortic valve innovation, advancing ...

Patients with severe aortic stenosis had comparable rates of death or disabling stroke, but the lead investigator cautions against an 'irrational' rush to move to younger patients ahead of the data.

Data shows, versus surgery, the Evolut™ transcatheter aortic valve replacement (TAVR) system delivers a numerically lower rate of all-cause mortality or disabling stroke at five years ...

In patients with symptomatic severe aortic stenosis at intermediate or higher surgical risk, CoreValve or Evolut transcatheter aortic valve implantation (TAVI) was associated with a lower 5-year ...

CHICAGO, IL—Five-year follow-up for patients with severe aortic stenosis and low surgical risk affirm the benefits of TAVI with a self-expanding, supra-annular valve compared with surgery, according ...

This had not been observed in last year's LANDMARK trial report, which showed that Myval (mostly Myval proper, not the Myval Octacor) met noninferiority criteria against Sapien and Evolut valves ...